SCHEMBL4337651

SCHEMBL4337651

O=C(Nc1cc2c(-c3cc4ccccc4s3)n[nH]c2cc1F)c1ccco1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 1/20 0.46
MAPK1 P28482 2/20 0.45
HSD17B10 Q99714 2/20 0.45
TP53 P04637 2/20 0.45
TSHR P16473 2/20 0.45
USP2 O75604 1/20 0.45
ATM Q13315 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
RAB9A P51151 6/20 0.44
NPC1 O15118 4/20 0.44
ITK Q08881 1/20 0.43
MAPKAPK2 P49137 1/20 0.42
MAPT P10636 5/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 3/20 0.41
KDM4E B2RXH2 2/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2862092 0.84 MAPK10 (0.49) MAPK10ITKMAPKAPK2PKM
SCHEMBL4337637 0.84 MAPK1 (0.45) MAPK10MAPK1HSD17B10TP53TSHR
SCHEMBL4340833 0.83 SMN1; SMN2 (0.47) MAPK1HSD17B10TP53TSHRTDP1
SCHEMBL4329381 0.80 MAPK10 (0.59) MAPK10RAB9ANPC1ITKMAPKAPK2
SCHEMBL2866702 0.79 MAPK10 (0.44) MAPK10MAPK1SMN1; SMN2ITKMAPKAPK2
SCHEMBL2867642 0.79 AURKA (0.49) MAPK10HSD17B10SMN1; SMN2RAB9ANPC1
SCHEMBL4342242 0.78 HSD17B10 (0.43) MAPK10MAPK1HSD17B10TP53TSHR
SCHEMBL4334072 0.78 HPGD (0.47) MAPK10MAPK1HSD17B10TP53TSHR
SCHEMBL2866652 0.76 TNIK (0.47) MAPK10ITKMAPKAPK2
SCHEMBL4333017 0.76 MAPK10 (0.49) MAPK10SMN1; SMN2ITKMAPKAPK2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPK10 29/4885MAPK1 1/4885HSD17B10 1699/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPK10 29/4885MAPK1 1/4885HSD17B10 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.